THERAVANCE BIOPHARMA INC (TBPH)

KYG8807B1068 - Common Stock

9.42  -0.07 (-0.74%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
55.3M
-23.09%		51.3M
-7.23%		57.424M
11.94%		75.815M
32.03%
EBITDA
YoY % growth
-231.79M
20.29%		-75.38M
67.48%		-51.291M
31.96%		-11.884M
76.83%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-237.7M
20.13%		-79.1M
66.72%		-53.292M
32.63%		-34.256M
35.72%
Operating Margin
-429.84%-154.19%-92.80%-45.18%
EPS
YoY % growth
-2.95
34.15%		-0.67
77.29%		-0.97
-44.78%		-0.66
32.21%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.26
25.98%
Revenue
Q2Q % growth		14.242M
36.94%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-12.802M
45.06%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.17
-13.33%		-0.15-0.02-12.11%
Q3 2023
Q2Q % growth		 -0.17
19.05%		-0.210.0420.51%
Q2 2023
Q2Q % growth		 -0.28
-211.11%		-0.21-0.07-30.72%
Q1 2023
Q2Q % growth		 -0.35
-59.09%		-0.25-0.10-39.30%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 17.565M
20.31%		18.038M-473K-2.62%
Q3 2023
Q2Q % growth		 15.7M
25.60%		15.302M398K2.60%
Q2 2023
Q2Q % growth		 13.7M
23.42%		15.729M-2.029M-12.90%
Q1 2023
Q2Q % growth		 10.4M
-21.21%		13.988M-3.588M-25.65%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-0.79% -3.25% -54.85% -5.86%
Revenue-6.39% -7.85% 0% -1.3%